Sidley represented Attralus, Inc., a clinical stage biopharmaceutical company focused on developing therapies to improve the lives of patients with systemic amyloidosis, in the close of its US$116 million Series B preferred stock financing. The financing was led by Logos Capital and included Janus Henderson Investors, Redmile Group, Samsara BioCapital, Sarissa Capital Management, Surveyor Capital (a Citadel company), and Vivo Capital. Founding investor, venBio Partners, also participated in the financing. Continue reading

See all Member News